Search - tctmd.com

Displaying 21 - 40 of 61

Sort: Relevancy | Date

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

Caitlin E. Cox

September 08, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

Shelley Wood

July 03, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Daily News

US Lawmakers Urged India to Rethink Stent Price Cap Ahead of State Visit

Shelley Wood

June 27, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

L.A. McKeown

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

Advertisement

No More Absorb BVS: Abbott Puts a Stop to Sales

TCTMD’s Top 10 Most Popular Stories for June 2017

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

US Lawmakers Urged India to Rethink Stent Price Cap Ahead of State Visit

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

TCTMD’s Top 10 Most Popular Stories for May 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Bioresorbable Scaffolds: Where Do We Go From Here?

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content